CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics

CNS PHARMACEUTICALS, INC. (CNSP): $1.17

0.05 (-4.10%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

CNSP Price/Volume Stats

Current price $1.17 52-week high $6.90
Prev. close $1.22 52-week low $0.61
Day low $1.17 Volume 32,100
Day high $1.28 Avg. volume 1,348,282
50-day MA $1.82 Dividend yield N/A
200-day MA $1.90 Market Cap 4.92M

CNSP Stock Price Chart Interactive Chart >


CNS PHARMACEUTICALS, INC. (CNSP) Company Bio


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.


CNSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream


Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that 200 of the expected 243 patients have now been enrolled in the Company's ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer.

Yahoo | September 7, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET.

Yahoo | September 5, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a

Yahoo | August 14, 2023

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones.

Yahoo | August 14, 2023

CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will participate in a fireside chat at Benzinga's Virtual Biotech Conference on Thursday, August 3, 2023 at 11:35 AM ET.

Yahoo | August 3, 2023

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo -33.14%
3-mo -50.21%
6-mo 7.34%
1-year -79.67%
3-year -97.83%
5-year N/A
YTD -51.25%
2022 -88.61%
2021 -60.54%
2020 -54.94%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!